^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

Phase 1 Results of Anti-PD-Ligand 1 (Durvalumab) & Lenalidomide in Patients with Cutaneous T Cell Lymphoma and Correlation with Programmed Death Ligand 1 Expression and Gene Expression Profile

Published date:
11/06/2019
Excerpt:
Pts are enrolled in sequential cohorts to receive durvalumab (fixed dose at 1500 mg) and dose escalation of lenalidomide...to characterize safety, efficacy and antitumor activity….Detectable levels of PD-L1 but low levels of ICOS are observed in responding pts vs. high PD-L1 and ICOS levels in non-responders.
DOI:
https://doi.org/10.1182/blood-2019-126358
Trial ID: